215 related articles for article (PubMed ID: 23354026)
1. The clinical value of dual-time point 18F-FDG PET/CT for differentiating extrahepatic cholangiocarcinoma from benign disease.
Choi EK; Yoo IeR; Kim SH; O JH; Choi WH; Na SJ; Park SY
Clin Nucl Med; 2013 Mar; 38(3):e106-11. PubMed ID: 23354026
[TBL] [Abstract][Full Text] [Related]
2. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
[TBL] [Abstract][Full Text] [Related]
3. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
[TBL] [Abstract][Full Text] [Related]
4. Preoperative 18F-FDG PET-CT maximum standardized uptake value predicts recurrence of biliary tract cancer.
Park MS; Lee SM
Anticancer Res; 2014 May; 34(5):2551-4. PubMed ID: 24778075
[TBL] [Abstract][Full Text] [Related]
5. Detection of Klatskin's tumor in extrahepatic bile duct strictures using delayed 18F-FDG PET/CT: preliminary results for 22 patient studies.
Reinhardt MJ; Strunk H; Gerhardt T; Roedel R; Jaeger U; Bucerius J; Sauerbruch T; Biersack HJ; Dumoulin FL
J Nucl Med; 2005 Jul; 46(7):1158-63. PubMed ID: 16000285
[TBL] [Abstract][Full Text] [Related]
6. Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging.
Kim JY; Kim MH; Lee TY; Hwang CY; Kim JS; Yun SC; Lee SS; Seo DW; Lee SK
Am J Gastroenterol; 2008 May; 103(5):1145-51. PubMed ID: 18177454
[TBL] [Abstract][Full Text] [Related]
7. Role of 18F-FDG PET/CT Imaging in Intrahepatic Cholangiocarcinoma.
Jiang L; Tan H; Panje CM; Yu H; Xiu Y; Shi H
Clin Nucl Med; 2016 Jan; 41(1):1-7. PubMed ID: 26402131
[TBL] [Abstract][Full Text] [Related]
8. Dual-time point 18F-FDG PET/CT scan for differentiation between 18F-FDG-avid non-small cell lung cancer and benign lesions.
Suga K; Kawakami Y; Hiyama A; Sugi K; Okabe K; Matsumoto T; Ueda K; Tanaka N; Matsunaga N
Ann Nucl Med; 2009 Jul; 23(5):427-35. PubMed ID: 19437097
[TBL] [Abstract][Full Text] [Related]
9. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic Performance and Prognostic Relevance of FDG Positron Emission Tomography/Computed Tomography for Patients with Extrahepatic Cholangiocarcinoma.
Kim NH; Lee SR; Kim YH; Kim HJ
Korean J Radiol; 2020 Dec; 21(12):1355-1366. PubMed ID: 32767862
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of 18F-fluorodeoxyglucose positron emission tomography in differential diagnosis and staging of cholangiocarcinomas.
Moon CM; Bang S; Chung JB; Park SW; Song SY; Yun M; Lee JD
J Gastroenterol Hepatol; 2008 May; 23(5):759-65. PubMed ID: 17931372
[TBL] [Abstract][Full Text] [Related]
12. The value of F-18 FDG PET in patients with primary sclerosing cholangitis and cholangiocarcinoma using visual and semiquantitative analysis.
Alkhawaldeh K; Faltten S; Biersack HJ; Ezziddin S
Clin Nucl Med; 2011 Oct; 36(10):879-83. PubMed ID: 21892037
[TBL] [Abstract][Full Text] [Related]
13. Differential diagnosis between (18)F-FDG-avid metastatic lymph nodes in non-small cell lung cancer and benign nodes on dual-time point PET/CT scan.
Suga K; Kawakami Y; Hiyama A; Sugi K; Okabe K; Matsumoto T; Ueda K; Tanaka N; Matsunaga N
Ann Nucl Med; 2009 Aug; 23(6):523-31. PubMed ID: 19444550
[TBL] [Abstract][Full Text] [Related]
14. Dual time point [18F]Flurodeoxyglucose (FDG) Positron Emission Tomography (PET)/Computed Tomography (CT) with water gastric distension in differentiation between malignant and benign gastric lesions.
Farghaly H; Alshareef M; Alqarni A; Sayed M; Nasr H
Eur J Radiol Open; 2020; 7():100268. PubMed ID: 32964074
[TBL] [Abstract][Full Text] [Related]
15. A stepwise approach using metabolic volume and SUVmax to differentiate malignancy and dysplasia from benign colonic uptakes on 18F-FDG PET/CT.
Oh JR; Min JJ; Song HC; Chong A; Kim GE; Choi C; Seo JH; Bom HS
Clin Nucl Med; 2012 Jun; 37(6):e134-40. PubMed ID: 22614211
[TBL] [Abstract][Full Text] [Related]
16. Dual-time-point FDG PET/CT for the evaluation of pediatric tumors.
Costantini DL; Vali R; Chan J; McQuattie S; Charron M
AJR Am J Roentgenol; 2013 Feb; 200(2):408-13. PubMed ID: 23345365
[TBL] [Abstract][Full Text] [Related]
17. Assessment of combination of contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of ovarian masses.
Tsuboyama T; Tatsumi M; Onishi H; Nakamoto A; Kim T; Hori M; Sakane M; Hori Y; Morii E; Hatazawa J; Tomiyama N
Invest Radiol; 2014 Aug; 49(8):524-31. PubMed ID: 24637584
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of dual-phase 18F-FDG PET/CT for diagnosing small pancreatic tumors.
Kawada N; Uehara H; Hosoki T; Takami M; Shiroeda H; Arisawa T; Tomita Y
Pancreas; 2015 May; 44(4):655-9. PubMed ID: 25815646
[TBL] [Abstract][Full Text] [Related]
19. The effectiveness of dual-phase 18F-FDG PET/CT in the detection of epithelial ovarian carcinoma: a pilot study.
Lee JK; Min KJ; So KA; Kim S; Hong JH
J Ovarian Res; 2014 Feb; 7():15. PubMed ID: 24499648
[TBL] [Abstract][Full Text] [Related]
20. Dual time point FDG-PET/CT imaging... Potential tool for diagnosis of breast cancer.
Zytoon AA; Murakami K; El-Kholy MR; El-Shorbagy E
Clin Radiol; 2008 Nov; 63(11):1213-27. PubMed ID: 18929039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]